A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance. - A Phase II Study of Pemetrexed in chemo-naive Elderly Patients with Lung Adenocarcinoma and An exploratory study on Mechanisms of chemotherapy resistance.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006113

Enrollment

Registered

2011-08-04

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Previously untreated lung adenocarcinoma

Interventions

Pemetrexed (500mg/m2) day 1,q3~5w until disease progression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically proven lung adenocarcinoma 2. No indication for platinum doublet therapy 3. With measurable lesion based on RECIST 4. Previously untreated 5. ECOG PS 0-2 6. 70 years or older 7. Adequate organ function 8. Eligible in case of controlled pleural effusion 9)Eligible in case of controlled brain metastases 10)Written informed consent

Exclusion criteria

Exclusion criteria: 1. Symptomatic brain metastasis 2. Massive pleural effusion 3. Hystory of active double cancer 4. History of uncontrollable diabetes mellitus, active angina pectoris, recent myocardial infaction, and severe complications 5. History of active infection

Design outcomes

Primary

Measure	Time frame
one year survival rate	—

Secondary

Measure	Time frame
overall survival, progression-free survival, objective response rate, adverse effects.	—

Countries

Japan

Contacts

Public ContactYoshitaka Seki

Jikei University Daisan-Hospital Division of Respirology, department of internal medicine

ms97-seki@jikei.ac.jp03-3480-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026